跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT04143581
NCT04143581撤回2 期

Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a Sequential OFF-ON-OFF Study With One-Month Empagliflozin Therapy Followed by One-Month Recovery Period

Mario Negri Institute for Pharmacological Research0 个研究点开始时间: 2021年9月3日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
主要终点
Measured Glomerular Filtration Rate (GFR)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Glomerular hyperfiltration is a major risk factor for accelerated glomerular filtration rate (GFR) decline and renal and cardiovascular events despite optimized conservative therapy with blood pressure and blood glucose (in diabetics) lowering medications and inhibitors of the Renin Angiotensin System (RAS) such as Angiotensin Converting Enzyme (ACE) inhibitors and/or Angiotensin Receptor Blockers (ARBs).

Progressive GFR decline initiated and sustained by glomerular hyperfiltration in subjects with diabetes, unhealthy obesity, hypertension and other risk factors, is paralleled by progressive glomerulosclerosis and loss of functioning nephrons.

The inhibition of the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubular segments of the nephrons appears to be an ideal, specific intervention to inhibit the tubulo-glomerular feedback and ameliorate glomerular hyperfiltration in subjects with absolute or relative hyperfiltration associated with unhealthy obesity or proteinuric chronic kidney disease (CKD). Indeed, by reducing tubular sodium reabsorption, SGLT2 inhibitors may enhance sodium chloride delivery to the macula densa, restore pre-glomerular resistances and therefore limit glomerular hyperperfusion and consequent hyperfiltration. Moreover, because of its natriuretic effects, SGLT2 inhibition therapy might reduce the sodium overload and volume expansion which, along with secondary hypertension, may further contribute to kidney hyperperfusion and glomerular hyperfiltration in obesity and CKD.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Male and female ≥ 18 years old;
  • •Increased risk of accelerated renal function loss because of absolute or relative hyperfiltration associated with unhealthy obesity or residual proteinuria defined as:
  • •Unhealthy obesity:
  • •BMI >30 kg/m^2 or waist circumference >94 cm in males and > 80 cm in females
  • •Metabolic syndrome, defined as the presence of at least three of the following criteria:
  • •Blood pressure>140/90 mmHg or controlled blood pressure under current antihypertensive treatment
  • •Triglyceride levels >150 mg/dL
  • •HDL<40 mg/dL in males <50 mg/dL in females
  • •Fasting blood glucose > 100 and <125 mg/dL
  • •Residual proteinuria:
  • •Urinary protein excretion >1g/24-h to <3g/24-h despite RAS inhibitor therapy with ACE inhibitors or ARBs;
  • •Blood pressure in recommended targets with or without blood pressure lowering medications;
  • •Estimated GFR > 60 ml/min/1.73m^2 (CKD-EPI formula);
  • •Female childbearing potential and non-sterile male must agree to use a method of contraception;
  • •Written informed consent

排除标准

  • •Type 1or 2 diabetic patients;
  • •Concomitant treatment with insulin or oral hypoglycemic agents;
  • •Nephrotic syndrome of any etiology;
  • •Patients with Autosomal Dominant Polycystic Kidney Disease;
  • •Symptomatic urinary tract lithiasis or obstruction;
  • •Ischemic kidney disease (because of possible excess risk of acute kidney injury upon SGLT2 inhibition associated reduction in sodium pool and kidney perfusion pressure);
  • •Rapidly progressive kidney disease defined by impairment of renal function within 2 weeks - 3 months (for the cohort of patients with residual proteinuria only) ;
  • •Active systemic autoimmune diseases;
  • •Treatment for glomerulopathies or systemic diseases with steroids or any other immunosuppressive agent within one year;
  • •Specific contraindication to SGLT2 inhibitor therapy;
  • •Heart failure with or without decreased systolic function;
  • •Uncontrolled hypertension or symptomatic hypotension;
  • •History of malignancy within 5 years of screening;
  • •Inability to fully understand the possible risks and benefits related to study participation;
  • •If female, the subject is pregnant or lactating or intending to become pregnant before, during, or within 90 days after last dose; or intending to donate ova during such time period;
  • •If male, the subject intends to donate sperm while on the study this study or for 90 days after last dose;
  • •Alcohol and drug abuse;
  • •Participation in another interventional clinical trial within the 4 weeks prior to screening.

研究组 & 干预措施

IMP

Experimental

干预措施: Empagliflozin 10 MG (Drug)

结局指标

主要结局

Measured Glomerular Filtration Rate (GFR)

时间窗: Changes from baseline to the end of one-month treatment period and one-month recovery period

GFR will be measured by the iohexol plasma clearance technique

次要结局

  • Fractional clearance of uric acid calculated by standard formulas(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Fractional clearance of free water calculated by standard formulas(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary glucose excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Fractional clearance of sodium calculated by standard formulas(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary urea excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary creatinine excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary output(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary protein excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary albumin excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary phosphate excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary sodium excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary potassium excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour urinary uric acid excretion(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Fractional clearance of total protein calculated by standard formulas(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Fractional clearance of albumin calculated by standard formulas(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Office blood pressure(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Indices of Quality of Life: questionnaire SF-36(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Glucose tolerance(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Fractional clearance of potassium calculated by standard formulas(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Glucose disposal rate(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour (day-time and night-time) blood pressure monitoring(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • 24 hour (day-time and night-time) heart rate monitoring(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Pulse wave velocity(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • other marker of vascular stiffness(Changes from baseline to the end of one-month treatment period and one-month recovery period)
  • Office heart rate(Changes from baseline to the end of one-month treatment period and one-month recovery period)

研究者

发起方
Mario Negri Institute for Pharmacological Research
申办方类型
Other
责任方
Sponsor

相似试验

已完成
不适用
The Effect of Patient Education Based on Nursing Model on Life Activities and Self-Care of Hemodialysis PatientsHemodialysis Complication
NCT04797234Muş Alparlan University93
已完成
不适用
Renal Insufficiency And Cardiovascular EventsCardiovascular Disease
NCT00715481Diabetic Nephropathy Study Group15,628
已完成
不适用
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMIST Elevation Myocardial Infarction
NCT03984071Dongying Zhang3
招募中
不适用
Influence on estimated glomerular filtration rate in patients with ischemic heart disease and hyperuricemia medicated by febuxostat.Ischemic heart disease patients with hyperuricemia
JPRN-UMIN000009160Osaka City University Department of Cardiovascular Medicine240
已完成
不适用
Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)Atherosclerosis
NCT02394743Korea University360
SGLT2 Inhibitors in Glomerular Hyperfiltration | 临床试验